Corbus Pharmaceuticals Holdings Inc Dossier
Qualitative Analysis
Business overview
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology and obesity. The company's pipeline is anchored by CRB-701, a next-generation antibody-drug conjugate (ADC) targeting Nectin-4-expressing solid tumors, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist designed for the treatment of obesity. Corbus is committed to bringing novel scientific approaches to well-understood biological pathways to help patients defeat serious illnesses.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing CRB-701, a next-generation Nectin-4 targeting antibody-drug conjugate (ADC), into registrational clinical trials. The company reached broad alignment with the FDA on a randomized controlled study design (TEMPO-1) comparing CRB-701 to investigator's choice of monotherapy in 2L OPSCC.
Expected impact: Potential accelerated approval based on objective response rate (ORR) and full approval based on overall survival (OS) benefit.
Developing CRB-913, a highly peripherally restricted oral CB1 inverse agonist, as a non-incretin alternative or combination therapy for chronic obesity management.
Expected impact: Establishment of a safe, well-tolerated oral weight loss therapy with minimal neuropsychiatric or gastrointestinal side effects.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Granted Corbus exclusive development and commercialization rights to CRB-701 (SYS6002) in the United States, Canada, the European Union, the United Kingdom, and Australia.
Terms: $7.5 million upfront payment, up to $130 million in potential development and regulatory milestones, up to $555 million in potential sales milestones, and tiered double-digit royalties on net sales.
Granted Kaken an exclusive license to develop, commercialize, and market Lenabasum in Japan for systemic sclerosis and dermatomyositis.
Terms: $27 million upfront payment, up to $173 million in potential regulatory, development, and sales milestones, plus double-digit royalties on sales in Japan.